Entacapone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Entacapone: From Parkinson's Disease to PLA2G6-Associated Neurodegeneration
One-Sentence Summary
Entacapone is a COMT inhibitor used as an adjunct to levodopa/carbidopa therapy in Parkinson's disease, extending dopamine precursor availability. The TxGNN model predicts it may be effective for PLA2G6-Associated Neurodegeneration, but currently no clinical trials and no publications support this specific prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson's disease (adjunct to levodopa therapy) — inferred from repurposing rationale text; no formal indication text or MOA data provided in this evidence pack |
| Predicted New Indication | PLA2G6-Associated Neurodegeneration |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on information present elsewhere in this evidence pack, entacapone is known as a COMT inhibitor co-administered with levodopa in Parkinson's disease, prolonging levodopa's central availability. Its efficacy in Parkinson's disease is well established.
For the top-ranked prediction, PLA2G6-Associated Neurodegeneration, the evidence pack provides no mechanistic rationale text, no clinical trials, and no literature. This is unusual compared to lower-ranked predictions in the same batch (e.g., rank 4 "juvenile parkinsonism of Hunt" and rank 7 "Lewy body dementia"), which do include reasoned mechanistic links to dopaminergic pathways. Without any supporting rationale or evidence, this top-ranked prediction should be treated as an unvalidated model output rather than a scientifically substantiated hypothesis — despite carrying the highest TxGNN score in this batch.
Notably, two other candidates in this same prediction set — Lewy body dementia (rank 7) and progressive supranuclear palsy-corticobasal syndrome (rank 10) — have documented literature and/or clinical trial signals tied to dopaminergic mechanisms shared with Parkinson's disease. These may warrant prioritization over PLA2G6-Associated Neurodegeneration for further evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Entacapone is not currently marketed in Norway (0 authorizations on record); no license data is available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (PLA2G6-Associated Neurodegeneration) has no supporting clinical trials, literature, or mechanistic rationale — it is a pure model output (L5) and should not proceed without further validation.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action from DrugBank — currently a High-severity data gap (DG002)
- Preclinical or mechanistic studies linking entacapone's COMT-inhibitory activity to PLA2G6-associated neurodegeneration pathology
- Consider evaluating the better-evidenced alternatives in this batch (Lewy body dementia, PSP-corticobasal syndrome) as higher-priority repurposing candidates for entacapone
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.